Erratum to: Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients (The Oncologist, (2017), 22, 1, (25-32), 10.1634/theoncologist.2016-0229);Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients

Oncologist

Volumn 22, Issue 1, 2017, Pages 25-32

  Tolaney, Sara M ^a   Ziehr, David R ^b   Guo, Hao ^a   Ng, Mei R ^c   Barry, William T ^a   Higgins, Michaela J ^b   Isakoff, Steven J ^b   Brock, Jane E ^d   Ivanova, Elena V ^a   Paweletz, Cloud P ^a   Demeo, Michelle K ^a   Ramaiya, Nikhil H ^a   Overmoyer, Beth A ^a   Jain, Rakesh K ^c   Winer, Eric P ^a   Duda, Dan G ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cabozantinib; Lymphocytes; Soluble MET; Triple negative breast cancer; Vascular endothelial growth factor receptor

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BIOLOGICAL MARKER; CABOZANTINIB; CARBONATE DEHYDRATASE IX; CD14 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; PLACENTAL GROWTH FACTOR; SCATTER FACTOR; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; ANILIDE; KDR PROTEIN, HUMAN; MET PROTEIN, HUMAN; PGF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; SCATTER FACTOR RECEPTOR; TUMOR MARKER; VEGFD PROTEIN, HUMAN;

ADULT; AGED; ANOREXIA; ARTICLE; BONE METASTASIS; BONE PAIN; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; INFECTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTATIC BREAST CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NATURAL KILLER T CELL; NAUSEA; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION; THROMBOEMBOLISM; TRIPLE NEGATIVE BREAST CANCER; WOUND DEHISCENCE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ADULT; AGED; ANILIDES; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PLACENTA GROWTH FACTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; TRIPLE NEGATIVE BREAST NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 85011349342     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1002/onco.13809     Document Type: Erratum

References (36)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. O’Brien KM, Cole SR, Tse CK et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010; 16:6100-6110.
3. Iqbal J, Ginsburg O, Rochon PA et al. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 2015;313:165-173.
4. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007;13: 4429-4434.
5. Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer [published correction appears in Breast Cancer Res Treat 2008;109:141]. Breast Cancer Res Treat 2008;109:123-139.
6. Gherardi E, Birchmeier W, Birchmeier C et al. Targeting MET in cancer: Rationale and progress. Nat Rev Cancer 2012;12:89-103.
7. Beviglia L, Matsumoto K, Lin CS et al. Expression of the c-Met/HGF receptor in human breast carcinoma: Correlation with tumor progression. Int J Cancer 1997; 74:301-309.
8. Jin L, Fuchs A, Schnitt SJ et al. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997;79:749-760.
9. Lengyel E, Prechtel D, Resau JH et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-682.
10. Raghav KP, Wang W, Liu S et al. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 2012;18: 2269-2277.
11. Tuck AB, Park M, Sterns EE et al. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148: 225-232.
12. Yamashita J, Ogawa M, Yamashita S et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-1633.
13. Ho-Yen CM, Green AR, Rakha EA et al. C-Met in invasive breast cancer: Is there a relationship with the basal-like subtype? Cancer 2014;120:163-171.
14. Zagouri F, Bago-Horvath Z, Rössler F et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013;108:1100-1105.
15. Gonzalez-Angulo AM, Chen H, Karuturi MS et al. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 2013;119:7-15.
16. Graveel CR, DeGroot JD, Su Y et al. Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci USA 2009;106:12909-12914.
17. Ponzo MG, Lesurf R, Petkiewicz S et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 2009; 106:12903-12908.
18. Yakes FM, Chen J, Tan J et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-2308.
19. Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1814-1823.
20. Elisei R, Schlumberger MJ, Müller SP et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639-3646.
21. Smith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-419.
22. Atkinson EN, Brown BW. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 1985;41:741-744.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
24. Basch E, Autio KA, Smith MR et al. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: Results from a phase 2 nonrandomized expansion cohort. Eur Urol 2015;67:310-318.
25. Sameni M, Tovar EA, Essenburg CJ et al. Cabozantinib (XL184) inhibits growth and invasion of preclinical TNBC models. Clin Cancer Res 2016;22: 923-934.
26. Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-338.
27. Leibowitz-Amit R, Pintilie M, Khoja L et al. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: A post hoc analysis of an extension cohort of a phase II trial. J TranslMed 2016;14:12.
28. Kwilas AR, Ardiani A, Donahue RN et al. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med 2014;12:294.
29. Kwilas AR, Donahue RN, Tsang KY et al. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenviron 2015;2:e677.
30. Escudier B. Subgroup analyses of meteor, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol 2016;34(suppl 2):499a.
31. Tolaney S, Guo H, BarryWet al. A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer. J Clin Oncol 2014;32(suppl 5):1106a.
32. Miles DW, Dieras V, Cortes J et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: Pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013;24:2773-2780.
33. Tolaney SM, Boucher Y, Duda DG et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci USA 2015; 112:14325-14330.
34. Lu KV, Chang JP, Parachoniak CA et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22:21-35.
35. Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012; 12:699-709.
36. Dieras V, Campone M, Yardley DA et al. Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer. Ann Oncol 2015;26: 1904-1910.